financetom
Business
financetom
/
Business
/
Gildan Activewear Up 2% in U.S. Pre-Market On Q2 Earnings and Revs Beat; Reconfirmed Guidance, Provided Three Year Outlook and Announced Buyback
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Gildan Activewear Up 2% in U.S. Pre-Market On Q2 Earnings and Revs Beat; Reconfirmed Guidance, Provided Three Year Outlook and Announced Buyback
Aug 1, 2024 6:17 AM

08:51 AM EDT, 08/01/2024 (MT Newswires) -- Apparel manufacturer Gildan Activewear Inc. ( GIL ) -- under the direction of a new board and reinstated chief executive, Glenn Chamandy -- was at last look up 2% in US premarket trade on a second quarter earnings and revenues beat, and as it reconfirmed its full year guidance and provided a three year outlook.

Giland also announced a Normal Course Issuer Bid to repurchase up to 10% of the company's public float. It noted capital returned to shareholders of US$182 million during the quarter through dividends and share repurchases.

The company's share price jumped 2.0% at last look to US$41.50 in NYSE pre-market trading following all the news.

Adjusted net earnings rose to US$124.7 million, or US$0.74 per share, from US$112.3 million, or US$0.63 per share. It beat a consensus forecast of US$0.72 at Capital IQ.

Net sales climbed to US$862.2 million from US$840.4 million. It beat a consensus forecast of US$851.53 million at Capital IQ.

Among other highlights, it reported operating margin of 16.4%, adjusted operating margin of 22.7%; and cash flow from operations of $140 million and free cash flow of $104 million.

The board declared a quarterly dividend of $0.205 per share, payable Sept. 16, to shareholders of record as of Aug. 22.

Meanwhile, for 2024, Gildan expects to book an adjusted diluted EPS in the range of US$2.92 to US$3.07, up between 13.5% and 18.5% year over year. Revenue growth for the full year is expected to be flat or up low-single digits. Capex is expected to come in at near 5% of net sales. Free cash flow is seen above 2023 levels driven by increased profitability, lower working capital investments and lower capex than in 2023.

For its three-year outlook, Gildan expects its net sales growth at a compound annual growth rate in the mid-single digit range. The company also sees its annual adjusted operating margin to further improve over the three-year period as compared to 2024.

Gildan also said it expects the adjusted diluted EPS growth at a compound annual growth rate in the mid-teen range.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sector Update: Consumer
Sector Update: Consumer
Jun 17, 2025
01:04 PM EDT, 06/17/2025 (MT Newswires) -- Consumer stocks were lower Tuesday afternoon, with the Consumer Staples Select Sector SPDR Fund (XLP) down 0.2% and the Consumer Discretionary Select Sector SPDR Fund (XLY) shedding 1.1%. In corporate news, JetBlue Airways ( JBLU ) Chief Executive Joanna Geraghty has told employees that the company is planning a series of cost cuts...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Vireo Growth Issues Second-Quarter Guidance
Vireo Growth Issues Second-Quarter Guidance
Jun 17, 2025
12:51 PM EDT, 06/17/2025 (MT Newswires) -- Vireo Growth ( VREOF ) Tuesday issued second-quarter guidance following three acquisitions of rival cannabis producers. The company expects pro forma revenue and adjusted EBITDA for the second quarter to be in the range of US$88 million to US$91 million, and US$23 million to US$24 million, respectively. The company said it is not...
Processa Pharmaceuticals Prices $7 Million Public Offering
Processa Pharmaceuticals Prices $7 Million Public Offering
Jun 17, 2025
12:47 PM EDT, 06/17/2025 (MT Newswires) -- Processa Pharmaceuticals ( PCSA ) said Tuesday it has priced a public offering to raise $7 million, with H.C. Wainwright as its placement agent. The company said it is offering 28 million shares and warrants to purchase up to the same number of shares at $0.25 per share and warrant. Investors can also...
Copyright 2023-2026 - www.financetom.com All Rights Reserved